Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422591 · ClinicalTrials.gov registry record · Phase 2
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT00422591: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00422591 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 175 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00422591, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find out if standard chemotherapy given with idarubicin and Cytarabine (ara-C) can help to control AML. Objectives: To determine the complete response (CR) rate, event-free survival (EFS) and overall survival (OS) of patients with newly diagnosed acute myeloid leukemia (AML) receiving standard combination chemotherapy with Idarubicin and cytarabine.
Primary Outcome
Complete Response (CR): Normalization of marrow (\< 5% blasts; \>10% cellularity) and of peripheral blood counts (no circulating blasts, neutrophil count \> 109/L, platelet count \> 100 x 109/L).
Interventions
- DRUG Cytarabine
- DRUG Idarubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2006-12 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
What the finished NCT00422591 record still lists
NCT00422591 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT00422591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00422591 about?
NCT00422591 is a clinical study titled "Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)". The goal of this clinical research study is to find out if standard chemotherapy given with idarubicin and Cytarabine (ara-C) can help to control AML. Objectives: To determine the complete response (CR) rate, event-free survival (EFS) and overall survival (OS) of patients with newly diagnosed acut...
What is the current status of trial NCT00422591?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2006-12. Estimated completion is 2017-01.
What interventions are being tested in trial NCT00422591?
The interventions under investigation include: Cytarabine (DRUG), Idarubicin (DRUG).
Who is sponsoring clinical trial NCT00422591?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00422591's enrollment target sits among peer trials
175 396th of 2000 higher than 1,605 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia